Strategies for suppressing angiogenesis in gynecological cancers

Drugs of Today

Volumn 43, Issue 4, 2007, Pages 259-273

  Ma, Wen W ^a   Jimeno, Antonio ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; ANGIOGENIN; ANGIOZYME; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; FIBROBLAST GROWTH FACTOR; FLUOROURACIL; GEMCITABINE; IMC 1C11; INTERLEUKIN 8; MONOCLONAL ANTIBODY VASCULAR ENDOTHELIAL GROWTH FACTOR TRAP; OXALIPLATIN; PACLITAXEL; PLACEBO; PROTEIN TYROSINE KINASE; PYK 787; RP 14610; RPI 4610; SORAFENIB; SUNITINIB; TAMOXIFEN; TAXANE DERIVATIVE; THALIDOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VATALANIB; MONOCLONAL ANTIBODY; RIBOZYME; VASCULOTROPIN A;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ANGIOGENESIS; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ARTERY THROMBOSIS; ARTHRALGIA; BLEEDING; BREAST CANCER; BULLOUS SKIN DISEASE; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENTEROCUTANEOUS FISTULA; ERYTHEMA NODOSUM LEPROSUM; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; GYNECOLOGIC CANCER; HAIR COLOR; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; INJECTION SITE REACTION; INTESTINE OBSTRUCTION; KIDNEY CANCER; KIDNEY CARCINOMA; LEUKOPENIA; LOW DRUG DOSE; LUNG DISEASE; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; PAIN; PERIPHERAL NEUROPATHY; PERITONEUM CANCER; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; RECOMMENDED DRUG DOSE; RECURRENT CANCER; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; SKIN COLOR; SOMNOLENCE; TERATOGENESIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; VERTIGO; VOMITING; WOUND HEALING IMPAIRMENT; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; FEMALE; FEMALE GENITAL TRACT TUMOR; NEOVASCULARIZATION (PATHOLOGY);

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DRUG DELIVERY SYSTEMS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN-TYROSINE KINASES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RNA, CATALYTIC; THALIDOMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34447317037     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2007.43.4.1062668     Document Type: Review

References (127)

1. Folkman, J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Eng J Med 1995, 333: 1757-63.
2. Folkman, J. Tumor angiogenesis: Therapeutic implications. N Eng J Med 1971, 285: 1182-6.
3. Hanahan, D., Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86: 353-64.
4. American Cancer Society. Cancer Facts & Figures 2007. American Cancer Society: Atlanta 2007.
5. Ozols, R.F., Bundy, B.N., Greer, B.E. et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2003, 21: 3194-200.
6. Ozols, R.F. Systemic therapy for ovarian cancer: Current status and new treatments. Semin Oncol 2006, 33 (2 Suppl. 6): S3-11.
7. Jain, R.K. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nature Medicine 2001, 7: 987.
8. Teicher, B.A., Sotomayor, E.A., Huang, Z.D. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 1992, 52: 6702-4.
9. Ferrara, N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999, 77: 527-43.
10. Kerbel, R.S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991, 13: 31-6.
11. Rugo, H.S. Bevacizumab in the treatment of breast cancer: Rationale and current data. Oncologist 2004, 9 (Suppl. 1): 43-9.
12. Miller, K.D., Chap, L.I., Holmes, F.A. et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005, 23: 792-9.
13. Hurwitz, H., Fehrenbacher, L., Novotny, W. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350: 2335-42.
14. Sandler, A., Gray, R., Brahmer, J. et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. J Clin Oncol 2005 ASCO Ann Meet Proc Vol 23, No 16S, Part I of II (June 1 Suppl.), 2005: 4.
15. Brower, V. Tumor angiogenesis - New drugs on the block. Nat Biotechnol 1999, 17: 963-8.
16. Tsai, J.C., Goldman, C.K., Gillespie, G.Y. Vascular endothelial growth factor in human glioma cell lines: Induced secretion by EGF, PDGF-BB, and bFGF. J Neurosurg 1995, 82: 864-73.
17. Potapova, O., Fakhrai, H., Baird, S., Mercola, D. Platelet-derived growth factor-B/v-sis confers a tumorigenic and metastatic phenotype to human T98G glioblastoma cells. Cancer Res 1996, 56: 280-6.
18. Cohen, T., Nahari, D., Cerem, L.W., Neufeld, G., Levi, B.Z. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996, 271: 736-41.
19. Akagi, Y., Liu, W., Zebrowski, B., Xie, K., Ellis, L.M. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res 1998, 58: 4008-14.
20. Akagi, Y., Liu, W., Xie, K., Zebrowski, B., Shaheen, R.M., Ellis, L.M. Regulation of vascular endothelial growth factor expression in human colon cancer by interleukin-1 beta. Br J Cancer 1999, 80: 1506-11.
21. Hicklin, D.J., Ellis, L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23: 1011-27.
22. Karkkainen, M.J., Petrova, T.V. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 2000, 19: 5598-605.
23. Cross, M.J., Dixelius, J., Matsumoto, T., Claesson-Welsh, L. VEGF-receptor signal transduction. Trends Biochem Sci 2003, 28: 488-94.
24. Senger, D.R., Galli, S.J., Dvorak, A.M., Perruzzi, C.A., Harvey, V.S., Dvorak, H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219: 983-5.
25. Leung, D.W., Cachianes, G., Kuang, W.J., Goeddel, D.V., Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246: 1306-9.
26. Carmeliet, P., Moons, L., Luttun, A. et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001, 7: 575-83.
27. Buchler, P., Reber, H.A., Buchler, M.W., Friess, H., Hines, O.J. VEGF-RII influences the prognosis of pancreatic cancer. Ann Surg 2002, 236: 738-49; discussion 49.
28. Kaipainen, A., Korhonen, J., Mustonen, T. et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 1995, 92: 3566-70.
29. Paavonen, K., Puolakkainen, P., Jussila, L., Jahkola, T., Alitalo, K. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol 2000, 156: 1499-504.
30. Volm, M., Koomagi, R., Mattern, J., Stammler, G. Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relationships to drug response in vitro. Anticancer Res 1997, 17: 99-103.
31. Brown, L.F., Berse, B., Jackman, R.W. et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995, 26: 86-91.
32. Guidi, A.J., Schnitt, S.J., Fischer, L. et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 1997, 80: 1945-53.
33. Brown, L.F., Berse, B., Jackman, R.W. et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993, 53: 4727-35.
34. Ellis, L.M., Takahashi, Y., Fenoglio, C.J., Cleary, K.R., Bucana, C.D., Evans, D.B. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur J Cancer 1998, 34: 337-40.
35. Uchida, S., Shimada, Y., Watanabe, G. et al. In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. Br J Cancer 1998, 77: 1704-9.
36. Brown, L.F., Berse, B., Jackman, R.W. et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993, 143: 1255-62.
37. Guidi, A.J., Abu-Jawdeh, G., Berse, B. et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 1995, 87: 1237-45.
38. Fujimoto, J., Sakaguchi, H., Hirose, R., Ichigo, S., Tamaya, T. Expression of vascular endothelial growth factor (VEGF) and its mRNA in uterine cervical cancers. Br J Cancer 1999, 80: 827-33.
39. Guidi, A.J., Abu-Jawdeh, G., Tognazzi, K., Dvorak, H.F., Brown, L.F. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. Cancer 1996, 78: 454-60.
40. Olson, T.A., Mohanraj, D., Carson, L.F., Ramakrishnan, S. Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res 1994, 54: 276-80.
41. Fukumura, D., Xavier, R., Sugiura, T. et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998, 94: 715-25.
42. Fox, S.B., Gasparini, G., Harris, A.L. Angiogenesis: Pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol 2001, 2: 278-89.
43. Gasparini, G., Toi, M., Gion, M. et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997, 89: 139-47.
44. Takahashi, Y., Tucker, S.L., Kitadai, Y. et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 1997, 132: 541-6.
45. Tjalma, W., Weyler, J., Weyn, B. et al. The association between vascular endothelial growth factor, microvessel density and clinicopathological features in invasive cervical cancer. Eur J Obstet Gynecol Reprod Biol 2000, 92: 251-7.
46. Loncaster, J.A., Cooper, R.A., Logue, J.P., Davidson, S.E., Hunter, R.D., West, C.M. Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer 2000, 83: 620-5.
47. Cheng, W.F., Chen, C.A., Lee, C.N., Chen, T.M., Hsieh, F.J., Hsieh, C.Y. Vascular endothelial growth factor in cervical carcinoma. Obstet Gynecol 1999, 93 (5 Pt. 1): 761-5.
48. Giatromanolaki, A., Sivridis, E., Brekken, R. et al. The angiogenic "vascular endothelial growth factor/flk-1(KDR) receptor" pathway in patients with endometrial carcinoma: Prognostic and therapeutic implications. Cancer 2001, 92: 2569-77.
49. Takebayashi, Y., Aklyama, S., Yamada, K., Akiba, S., Aikou, T. Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer 1996, 78: 226-31.
50. Mattern, J., Stammler, G., Koomagi, R., Wallwiener, D., Kaufmann, M., Volm, M. Association of vascular endothelial growth factor expression with tumor cell proliferation in ovarian carcinoma. Anticancer Res 1997, 17: 621-4.
51. Ogawa, S., Kaku, T., Kobayashi, H. et al. Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: A special review for clear cell adenocarcinoma. Cancer Lett 2002, 176: 111-8.
52. Fujimoto, J., Sakaguchi, H., Aoki, I., Khatun, S., Tamaya, T. Clinical implications of expression of vascular endothelial growth factor in metastatic lesions of ovarian cancers. Br J Cancer 2001, 85: 313-6.
53. Oehler, M.K., Caffier, H. Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer. Anticancer Res 2000, 20: 5109-12.
54. Dias, S., Hattori, K., Heissig, B. et al. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xeno-transplanted human leukemias. Proc Natl Acad Sci USA 2001, 98: 10857-62.
55. Bellamy, W.T., Richter, L., Frutiger, Y., Grogan, T.M. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999, 59: 728-33.
56. Decaussin, M., Sartelet, H., Robert, C. et al. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF- R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): Correlation with angiogenesis and survival. J Pathol 1999, 188: 369-77.
57. Ferrer, F.A., Miller, L.J., Lindquist, R. et al. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 1999, 54: 567-72.
58. Lacal, P.M., Failla, CM., Pagani, E. et al. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol 2000, 115: 1000-7.
59. Price, D.J., Miralem, T., Jiang, S., Steinberg, R., Avraham, H. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 2001, 12: 129-35.
60. Dias, S., Hattori, K., Zhu, Z. et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000, 106: 511-21.
61. Hayashibara, T., Yamada, Y., Miyanishi, T. et al. Vascular endothelial growth factor and cellular chemotaxis: A possible autocrine pathway in adult T-cell leukemia cell invasion. Clin Cancer Res 2001, 7: 2719-26.
62. Fan, F., Wey, J.S., McCarty, M.F. et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 2005, 24: 2647-53.
63. Wu, Y., Hooper, A.T., Zhong, Z. et al. The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int J Cancer 2006, 119: 1519-29.
64. Kim, K.J., Li, B., Houck, K., Winer, J., Ferrara, N. The vascular endothelial growth factor proteins: Identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992, 7: 53-64.
65. Presta, L.G., Chen, H., O'Connor, S.J. et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57: 4593-9.
66. Kabbinavar, F., Hurwitz, H.I., Fehrenbacher, L. et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21: 60.
67. Giantonio, B.J., Catalano, P.J., Meropol, N.J. et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol, 2005 ASCO Ann Meet Proc Vol 23, No 16S, Part I of II (June 1 Suppl.), 2005: 2.
68. Monk, B.J., Choi, D.C., Pugmire, G., Burger, R.A. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2005, 96: 902-5.
69. Bidus, M.A., Webb, J.C., Seidman, J.D., Rose, G.S., Boice, C.R., Elkas, J.C. Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms. Gynecol Oncol 2006, 102: 5-7.
70. Wright, J.D., Hagemann, A., Rader, J.S. et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. Cancer 2006, 107: 83-9.
71. Conn, D.E., Valmadre, S., Resnick, K.E., Eaton, L.A., Copeland, L.J., Fowler, J.M. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol 2006, 102: 134-9.
72. Monk, B.J., Han, E., Josephs-Cowan, C.A., Pugmire, G., Burger, R.A. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2006, 102: 140-4.
73. Burger, R.A., Sill, M., Monk, B.J., Greer, B.E., Sorosky, J. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study. J Clin Oncol, 2005 ASCO Ann Meet Proc Vol 23, No 16S, Part I of II (June 1 Suppl.), 2005: 5009.
74. Cannistra, S.A., Matulonis, U., Penson, R. et al. Bevacizumab in patients with advanced platinum-resistant ovarian cancer. Journal of Clin Oncol, 2006 ASCO Ann Meet Proc Part I, Vol 24, No 18S (June 20 Suppl.), 2006: 5006.
75. Garcia, A.A., Oza, A.M., Hirte, H.W. et al. Interim report of a phase II clinical trial of bevacizumab (Bev) and low-dose metronom ic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial. J Clin Oncol, 2005 ASCO Ann Meet Proc Vol 23, No 16S, Part I of II (June 1 Suppl.), 2005: 5000.
76. Yang, J.C., Haworth, L., Sherry, R.M. et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349: 427-34.
77. Aghajanian, C. The role of bevacizumab in ovarian cancer - An evolving story. Gynecol Oncol 2006, 102: 131-3.
78. Carboplatin and paclitaxel with or without bevacizumab in treating patients with stage III or stage IV ovarian epithelial or primary peritoneal cancer. Available at: http://www.clinicaltrials.gov/ct/show/NCT00262847.
79. ICON7: A randomised, two-arm, multicentre Gynaecologic Cancer InterGroup trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients with epithelial ovarian cancer. Available at: http://www.ncrn.org.uk/portfolio/data.asp?ID=1763.
80. Johnson, D.H., Fehrenbacher, L., Novotny, W.F. et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22: 2184-91.
81. Wright, J.D., Viviano, D., Powell, M.A. et al. Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol 2006, 103: 489-93.
82. Bevacizumab in treating patients with persistent or recurrent cancer of the cervix. Available at: http://www.clinicaltrials.gov/ct/show/ NCT00025233.
83. Bevacizumab, radiation therapy, and cisplatin in treating patients with previously untreated locally advanced cervical cancer (RTOG). Available at: http://www.clinicaltrials.gov/ct/show/NCT00369122.
84. Kim, E.S., Serur, A., Huang, J. et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA 2002, 99: 11399-404.
85. Holash, J., Davis, S., Papadopoulos, N. et al. VEGF-Trap: A VEGF blocker with potent anti tumor effects. Proc Natl Acad Sci USA 2002, 99: 11393-8.
86. Huang, J., Frischer, J.S., Serur, A. et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 2003, 100: 7785-90.
87. Byrne, A.T., Ross, L., Holash, J. et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003, 9: 5721-8.
88. Dupont, J., Rothenberg, M.L., Springs, D.R. et al. Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors. J Clin Oncol, 2005 ASCO Ann Meet Proc Vol 23, No 16S, Part I of II (June 1 Suppl.), 2005: 3029.
89. Study of the effect of intravenous AVE0005 (VEGF Trap) in advanced ovarian cancer patients with recurrent symptomatic malignant ascites. Available at: http://www.clinicaltrials.gov/ct/show/NCT00327444.
90. Wilhelm, S.M., Carter, C., Tang, L. et al. BAY 43-9006 exhibits broad-spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64: 7099-109.
91. Strumberg, D., Richly, H., Hilger, R.A. et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005, 23: 965-72.
92. Escudier, B. Randomized phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). 13th Eur Cancer Conf (ECCO 13), Paris 2005, Abst 794.
93. Sorafenib in treating patients with persistent or recurrent ovarian epithelial or peritoneal cancer (GOG). Available at: http://www. clinicaltrials.gov/ct/show/NCT00093626.
94. Garofalo, A., Naumova, E., Manenti, L. et al. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Clin Cancer Res 2003, 9: 3476-85.
95. Kuenen, B.C., Giaccone, G., Ruijter, R. et al. Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies. Clin Cancer Res 2005, 11: 6240-6.
96. Sessa, C., Vigano, L., Grasselli, G. et al. Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing. Eur J Cancer 2006, 42: 171-8.
97. O'Farrell, A.M., Abrams, T.J., Yuen, H.A. et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003, 101: 3597-605.
98. Abrams, T.J., Murray, L.J., Pesenti, E. et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003, 2: 1011-21.
99. Abrams, T.J., Lee, L.B., Murray, L.J., Pryer, N.K., Cherrington, J.M. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003, 2: 471-8.
100. O'Farrell, A.M., Foran, J.M., Fiedler, W. et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003, 9: 5465-76.
101. Faivre, S., Delbaldo, C., Vera, K. et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006, 24: 25-35.
102. Motzer, R.J., Rini, B.I., Bukowski, R.M. et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295: 2516-24.
103. A phase II study of sunitinib (SU11248; NSC 736511; IND 74019) in patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Available at: http://www.clinicaltrials.gov/ct/show/NCT0038803.
104. Wood, J.M., Bold, G., Buchdunger, E. et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000, 60: 2178-89.
105. Drevs, J., Muller-Driver, R., Wittig, C. et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 2002, 62: 4015-22.
106. Thomas, A.L., Morgan, B., Horsfield, M.A. et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 2005, 23: 4162-71.
107. Tyagi, P. Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: Preliminary results from the CONFIRM-1 trial. Clin Colorectal Cancer 2005, 5: 24-6.
108. Koehne, C., Bajetta, E., Lin, E. et al. Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). J Clin Oncol, 2006 ASCO Ann Meet Proc Part I Vol 24, No 18S (June 20 Suppl.), 2006: 3508.
109. Joensuu, H., de Braud, F., Coco, P. et al. A phase II, open-label study of PTK787/ZK222584 in the treatment of metastatic gastrointestinal stromal tumors (GISTs) resistant to imatinib mesylate. J Clin Oncol, 2006 ASCO Ann Meet Proc Part I Vol 24, No 18S (June 20 Suppl.), 2006: 9531.
110. Anthony, L.B., Cronin, M., O'Dorisio, T., Odorisio, S. An open-label phase II study evaluating the safety and efficacy of PTK787 in patients with progressive metastatic neuroendocrine cancer. J Clin Oncol, 2006 ASCO Ann Meet Proc Part I Vol 24, No 18S (June 20 Suppl.), 2006: 14124.
111. Kuo, T., Fitzgerald, A., Kaiser, H., Sikic, B.I., Fisher, G.A. A phase I study of the VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK 222584) and gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol, 2006 ASCO Ann Meet Proc Part I Vol 24, No 18S (June 20 Suppl.), 2006: 4122.
112. Gauler, T.C., Fischer, B., Soria, J. et al. Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 orally adminis tered once daily at 1,250 mg as second-line monotherapy in patients (pts) with stage IIIB or stage IV non-small cell lung cancer (NSCLC). J Clin Oncol, 2006 ASCO Ann Meet Proc Part I Vol 24, No 18S (June 20 Suppl.), 2006: 7195.
113. Koch, I., Baron, A., Roberts, S. etal. Influence of hepatic dysfunction on safety, tolerability and pharmacokinetics (PK) of PTK787/ZK 222584 in patients (Pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol, 2005 ASCO Ann Meet Proc Vol 23, No 16S, Part I of II (June 1 Suppl.), 2005: 4134.
114. Xu, L., Yoneda, J., Herrera, C., Wood, J., Killion, J.J., Fidler, I.J. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol 2000, 16: 445-54.
115. Schroder, W., Campone, M., Abadie, P. et al. A phase IB, open label, safety and pharmacokinetic (PK) study of escalating doses of PTK787/ZK 222584 (PTK/ZK) in combination with paclitaxel and carboplatin in patients (Pts) with stage IC to IV epithelial ovarian cancer (EOC). J Clin Oncol, 2006 ASCO Ann Meet Proc Part I Vol 24, No 18S (June 20 Suppl.), 2006: 5075.
116. Weng, D.E., Usman, N. Angiozyme: A novel angiogenesis inhibitor. Curr Oncol Rep 2001, 3: 141-6.
117. Weng, D.E., Masci, P.A., Radka, S.F. et al. A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors. Mol Cancer Ther 2005, 4: 948-55.
118. Kobayashi, H., Eckhardt, S.G., Lockridge, J.A. et al. Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2005, 56: 329-36.
119. Franks, M.E., Macpherson, G.R., Figg, W.D. Thalidomide. Lancet 2004, 363: 1802-11.
120. Kumar, S., Witzig, T.E., Rajkumar, S.V. Thalidomide: Current role in the treatment of non-plasma cell malignancies. J Clin Oncol 2004, 22: 2477-88.
121. D'Amato, R.J., Loughnan, M.S., Flynn, E., Folkman, J. Thalidomide is an inhibitor of an giogenesis. Proc Natl Acad Sci USA 1994, 91:4082-5.
122. Verheul, H.M., Panigrahy, D., Yuan, J., D'Amato, R.J. Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits. Br J Cancer 1999, 79: 114-8.
123. Eisen, T., Boshoff, C., Mak, I. et al. Continuous low-dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000, 82: 812-7.
124. Ndubisi, B., Ciricano, F., Finkler, N. Use of thalidomide as consolidation therapy in ovarian and primary peritoneal cancers. J Clin Oncol 2004, ASCO Ann Meet Proc (Post-Meeting Edition) Vol 22, No 14S (July 15 Suppl.), 2004: 5154.
125. Abramson, N., Stokes, P.K., Luke, M., Marks, A.R., Harris, J.M. Ovarian and papillary-serous peritoneal carcinoma: Pilot study with thalidomide. J Clin Oncol 2002, 20: 1147-9.
126. Carboplatin with or without thalidomide in treating patients with ovarian epithelial cancer. Available at: http://www.clinicaltrials.gov/ct/ show/NCT00004876.
127. Tamoxifen compared with thalidomide in treating women with ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. Available at: http://www.clinicaltrials.gov/ct/show/NCT00041080.